Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Research & Development (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Research & Development for 7 consecutive years, with $17.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 60.75% year-over-year to $17.9 million, compared with a TTM value of $129.6 million through Dec 2025, down 25.33%, and an annual FY2025 reading of $129.6 million, down 25.33% over the prior year.
  • Research & Development was $17.9 million for Q4 2025 at Keros Therapeutics, down from $19.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $49.2 million in Q3 2024 and bottomed at $10.0 million in Q2 2021.
  • Average Research & Development over 5 years is $29.0 million, with a median of $28.0 million recorded in 2022.
  • The sharpest move saw Research & Development soared 133.21% in 2022, then tumbled 60.75% in 2025.
  • Year by year, Research & Development stood at $18.8 million in 2021, then skyrocketed by 32.04% to $24.9 million in 2022, then soared by 50.77% to $37.5 million in 2023, then rose by 21.71% to $45.6 million in 2024, then crashed by 60.75% to $17.9 million in 2025.
  • Business Quant data shows Research & Development for KROS at $17.9 million in Q4 2025, $19.5 million in Q3 2025, and $43.5 million in Q2 2025.